Paratek's Omadacycline May Face Mortality Questions With Proposed Pneumonia Indication

US FDA advisory committee will consider "noteworthy" imbalance in deaths in Paratek's trial in community-acquired bacterial pneumonia; agency could not determine cause, briefing documents note.